An observational study in Parkinson s Disease, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University Hospital, Clermont-Ferrand · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand — 5 open to participants now, 5 under way, none of them phase 3. Parkinson Disease · University Hospital, Clermont-Ferrand.
Among the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand, this one is one of 3 that started in 2026, is one of 2 observational ones, and was the 23rd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →5 of the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–75 · Healthy volunteers
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–90
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–80
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 46 across the 23 interventional studies, 250 across the 2 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
2 of the studies in Parkinson Disease by University Hospital, Clermont-Ferrand that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07702266University Hospital, Clermont-FerrandPrimary Parkinsonian Pain: Clinical Association and Phenotype | 2027-09-30 |
| NCT07813156University Hospital, Clermont-FerrandIdiopathic Parkinson's Disease: Interest of an Early Group-Based Cognitive Rehabilitation Program (LIFECOG-PD) | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Among the different types of pain observed in Parkinson's disease, primary parkinsonian pain (PPP) is the most severe, the most difficult to treat, but also the least well characterized and the hardest to describe, not only by patients but also by neurologists. Consequently, PPP remains difficult to identify, even for clinicians with expertise in Parkinson's disease.
Nevertheless, patients with Parkinson's disease who experience PPP appear to exhibit certain demographic and clinical characteristics that may help distinguish them from other patients, including a poorer motor response to levodopa, a stronger association with sleep disturbances, and cognitive and behavioral features such as impulse control disorders (ICDs). PPP may therefore be associated with a specific disease phenotype supported by distinct pathophysiological mechanisms.
Recently, a disease progression model proposed the existence of a "Brain-First" subtype (characterized by disease onset in the brainstem) and a "Body-First" subtype (characterized by disease onset in the gastrointestinal system). Several clinical markers appear to distinguish these subtypes, notably the presence of REM sleep behavior disorder (RBD), which has been associated with the Body-First phenotype.
The association between PPP and RBD, as well as between PPP and the Body-First subtype, has never been investigated. We hypothesize that PPP may be associated with several clinical markers of the Body-First phenotype. Identifying such associations could facilitate the routine clinical diagnosis of PPP and, consequently, improve its management, which remains inadequate at present.
The primary objective is to assess the proportion of patients with primary parkinsonian pain according to the presence of probable RBD in Parkinson's disease.
This prospective, cross-sectional, non-interventional category 3 study (RIPH 3) will be conducted in 300 patients. Patients contacted through the France Parkinson Association and interested in participating in the study will be able to access the online questionnaire via a QR code or a web link. Completion of the questionnaire is expected to take no more than 15 minutes. This self-administered questionnaire will include collection of general data (age, sex, disease duration, initial motor symptoms, side of symptom onset predominance, and comorbidities), assessments of pain, migraine, sleep, constipation, olfaction, anxiety and depression and impulse control disorders.
Patients will be contacted through the France Parkinson Association. If interested in the study, they will be able to access the online questionnaire hosted on the REDCap platform via a QR code or a web link.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a diagnosis of Parkinson's disease confirmed by a neurologist
Other: Online self-administered questionnaire
Completion of the questionnaire is expected to take no more than 15 minutes. This self-administered questionnaire will include collection of general data (age, sex, disease duration, initial motor symptoms, side of symptom onset predominance, and comorbidities), assessments of pain, migraine, sleep, constipation, olfaction, anxiety and depression and impulse control disorders.
Presence of primary parkinsonian pain according to the 3PDQ questionnaire
This self-questionnaire is completed by the patient during the inclusion visit
Time frame: at day 0
Probable REM sleep behavior disorder (RBD), as identified using the RBD-1Q (REM Sleep Behavior Disorder Single-Question Screen).
This self-questionnaire is completed by the patient during the inclusion visit
Time frame: at day 0
Presence of anosmia
Self-reported olfactory dysfunction
Time frame: at day 0
Presence of constipation
Self-reported constipation dysfunction
Time frame: at day 0
Presence of impulsive control disorders
Self reported impulse control disorders
Time frame: at day 0
Presence of Anxiety and/or depression according the HADs (Hospital Anxiety and Depression scale)
This self-questionnaire is completed by the patient during the inclusion visit
Time frame: at day 0
Presence of RBD according the RBD SQ (RBD-Screening Questionnaire)
This self-questionnaire is completed by the patient during the inclusion visit
Time frame: at day 0
Pain intensity according an EVA scale
patients will evaluate their pain with an EVA scale at inclusion visit
Time frame: at day 0
Presence of comorbidities
Patients will report if they had comorbidities such as diabete or osteoarticular disorders.
Time frame: at day 0
presence of migraines
patient will report if he had migraines
Time frame: at day 0
Current antiparkinsonian and analgesic treatments
Patient will report his current antiparkinsonian and analgesic treatments
Time frame: at day 0
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Sep 2027, 10 months after the start.
Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 10 months is below that.
Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →